KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia

Leukemia. 2010 May;24(5):1052-5. doi: 10.1038/leu.2010.13. Epub 2010 Feb 18.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adaptor Proteins, Signal Transducing
  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Chromosomes, Human, Pair 5 / genetics
  • Chromosomes, Human, Pair 9 / genetics
  • Cytoskeletal Proteins
  • Humans
  • Imatinib Mesylate
  • In Situ Hybridization, Fluorescence
  • Male
  • Myeloproliferative Disorders / complications
  • Myeloproliferative Disorders / drug therapy*
  • Myeloproliferative Disorders / genetics*
  • Oncogene Proteins, Fusion / genetics*
  • Piperazines / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Receptor, Platelet-Derived Growth Factor beta / genetics*
  • Thrombocytosis / drug therapy
  • Thrombocytosis / etiology*
  • Translocation, Genetic
  • Tumor Suppressor Proteins / genetics*

Substances

  • Adaptor Proteins, Signal Transducing
  • Antineoplastic Agents
  • Benzamides
  • Cytoskeletal Proteins
  • KANK1 protein, human
  • Oncogene Proteins, Fusion
  • Piperazines
  • Pyrimidines
  • Tumor Suppressor Proteins
  • Imatinib Mesylate
  • Receptor, Platelet-Derived Growth Factor beta